In addition, Kong et al. have reported that the hypoxic-inducible factor 1α (HIF1α)/VEGFA pathway was involved in the angiogenesis of residual liver cancer after iRFA treatment, and bevacizumab, which targets VEGFA, inhibited tumor growth and angiogenesis in iRFA model cells [6]. The gene discussed is HIF1A; the disease is neoplasm.